Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of IndoVac in Healthy Adults
NCT05228613Phase 1Completed
- Sponsor
- Bio Farma
- Start
- Feb 2022
- Primary completion
- Aug 2022
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of IndoVac in coronavirus disease 2019 (COVID-19) (5 arms), sponsored by Bio Farma. Primary endpoint: Safety of the vaccine. Started Feb 2022; status: completed.
02
Drugs
IndoVac
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05228613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05228613.